AU2002322762B2 - Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans - Google Patents

Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans Download PDF

Info

Publication number
AU2002322762B2
AU2002322762B2 AU2002322762A AU2002322762A AU2002322762B2 AU 2002322762 B2 AU2002322762 B2 AU 2002322762B2 AU 2002322762 A AU2002322762 A AU 2002322762A AU 2002322762 A AU2002322762 A AU 2002322762A AU 2002322762 B2 AU2002322762 B2 AU 2002322762B2
Authority
AU
Australia
Prior art keywords
polypeptide
nucleic acid
receptor
hbd
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002322762A
Other languages
English (en)
Other versions
AU2002322762A1 (en
Inventor
Jeffrey A. Loeb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2002322762A1 publication Critical patent/AU2002322762A1/en
Application granted granted Critical
Publication of AU2002322762B2 publication Critical patent/AU2002322762B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002322762A 2001-07-31 2002-07-31 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans Ceased AU2002322762B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30856301P 2001-07-31 2001-07-31
US60/308,563 2001-07-31
PCT/US2002/024053 WO2003012045A2 (en) 2001-07-31 2002-07-31 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans

Publications (2)

Publication Number Publication Date
AU2002322762A1 AU2002322762A1 (en) 2003-05-29
AU2002322762B2 true AU2002322762B2 (en) 2008-10-16

Family

ID=23194471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322762A Ceased AU2002322762B2 (en) 2001-07-31 2002-07-31 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans

Country Status (8)

Country Link
US (1) US7527794B2 (enExample)
EP (1) EP1456239B1 (enExample)
JP (1) JP4314113B2 (enExample)
AT (1) ATE427317T1 (enExample)
AU (1) AU2002322762B2 (enExample)
CA (1) CA2455830C (enExample)
DE (1) DE60231833D1 (enExample)
WO (1) WO2003012045A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271902B2 (en) * 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US20110034383A1 (en) * 2007-10-15 2011-02-10 Institut Pasteur Cxcl12 gamma a chemokine and uses thereof
EP2346526A2 (en) * 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2020142587A1 (en) 2019-01-03 2020-07-09 The Board Of Trustees Of The University Of Illinois Method and kit for treating a neurodegenerative disease
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5665862A (en) * 1992-09-29 1997-09-09 President And Fellows Of Harvard College Neurotrophic factor
WO1999014323A1 (en) * 1997-09-17 1999-03-25 Urs Eppenberger Heregulin-gamma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP2000510879A (ja) 1995-09-05 2000-08-22 ケンブリッジ ニューロサイエンス，インコーポレイテッド 特異的なオリゴ糖−ニューレグリン相互作用のためのアナログおよびその使用
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO1998043649A2 (en) 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
GB2363714B (en) 1998-04-23 2004-03-03 Vladimir Leko Herbal composition and medicament against diabetes mellitus type II manufactured thereof
CA2325919C (en) * 1999-01-29 2009-07-21 Kaneka Corporation Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
US5665862A (en) * 1992-09-29 1997-09-09 President And Fellows Of Harvard College Neurotrophic factor
WO1999014323A1 (en) * 1997-09-17 1999-03-25 Urs Eppenberger Heregulin-gamma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Meier et al, Journal of Cell Biology, vol.141 (1998) pp.715-726 *

Also Published As

Publication number Publication date
EP1456239A4 (en) 2005-04-27
JP4314113B2 (ja) 2009-08-12
CA2455830A1 (en) 2003-02-13
US20050107601A1 (en) 2005-05-19
WO2003012045A3 (en) 2004-07-01
ATE427317T1 (de) 2009-04-15
US7527794B2 (en) 2009-05-05
EP1456239A2 (en) 2004-09-15
DE60231833D1 (de) 2009-05-14
EP1456239B1 (en) 2009-04-01
CA2455830C (en) 2012-10-09
JP2005500052A (ja) 2005-01-06
WO2003012045A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
JP3595552B2 (ja) ヘレグリンの構造、生産および用途
JP3039802B2 (ja) 繊維芽細胞成長因子のための受容体
US5367060A (en) Structure, production and use of heregulin
US7341996B2 (en) Processed vascular endothelial growth factor-B polypeptides
Funakoshi et al. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons
EP1456239B1 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
PL212078B1 (pl) Modyfikowany propeptyd BMP-11, jego zastosowanie i sposób wytwarzania, kodująca go cząsteczka kwasu nukleinowego, zawierające je kompozycje farmaceutyczne oraz rekombinowana komórka
JP2001523951A (ja) 血管内皮増殖因子ｃ（ｖｅｇｆ−ｃ）タンパク質およびその遺伝子、変異体、ならびにその使用
JP2003159083A (ja) 新規な神経栄養因子
JPH11509187A (ja) 内皮細胞増殖の調節
AU2002322762A1 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
BRPI0608769A2 (pt) variantes de eritropoietina
Seno et al. Purification and characterization of a recombinant human cripto-1 protein
US7994123B2 (en) Hybrid proteins with ErbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US9683222B2 (en) Broad spectrum ErBB ligand binding molecules and methods for preparing and using them
JPH05229957A (ja) Ｍｋタンパク質
Moscatelli et al. Fibroblast growth factors
CN101611150A (zh) 二价ErbB配体结合分子及其制备和使用方法
AU2007202554A1 (en) Receptor Ligand VEGF-C
MXPA98003767A (en) Receivers of the neurotrophic factor derived from cell line gl

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired